UK-371804 is primarily utilized in research settings as a selective inhibitor of phosphodiesterase 4 (PDE4), which regulates cyclic AMP levels and is involved in inflammatory and immune responses. Its application is significant in studying inflammatory pathways and related diseases, such as asthma, rheumatoid arthritis, psoriasis, and chronic obstructive pulmonary disease (COPD). By inhibiting PDE4, it helps researchers understand the mechanisms underlying inflammation and evaluate potential therapeutic strategies. Additionally, it is used in preclinical studies to explore its efficacy in modulating immune responses, its potential in treating neurological conditions like Alzheimer's and Parkinson's disease due to PDE4's role in neuronal communication and brain inflammation, and its overall potential as a treatment for conditions driven by inflammatory processes. Research remains experimental, requiring further studies to confirm efficacy and safety before clinical use.